Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Up 125.3% in January

Repare Therapeutics Inc. (NASDAQ:RPTX) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest totaling 437,896 shares, a growth of 125.3% from the December 31st total of 194,336 shares. Based on an average daily trading volume, of 984,565 shares, the days-to-cover ratio is currently 0.4 days. Currently, 1.1% of the shares of the company are sold short. Currently, 1.1% of the shares of the company are sold short. Based on an average daily trading volume, of 984,565 shares, the days-to-cover ratio is currently 0.4 days.

Repare Therapeutics Trading Up 0.8%

Shares of RPTX stock traded up $0.02 on Friday, reaching $2.65. 1,219,900 shares of the company’s stock were exchanged, compared to its average volume of 947,968. The company’s fifty day simple moving average is $2.39 and its 200 day simple moving average is $1.95. The stock has a market capitalization of $114.24 million, a PE ratio of -1.57 and a beta of 0.97. Repare Therapeutics has a 52 week low of $0.89 and a 52 week high of $2.66.

Repare Therapeutics (NASDAQ:RPTX) last issued its earnings results on Friday, November 14th. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.43. The company had revenue of $11.62 million during the quarter, compared to the consensus estimate of $7.50 million. As a group, sell-side analysts predict that Repare Therapeutics will post -2.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Wall Street Zen raised Repare Therapeutics to a “hold” rating in a report on Saturday, November 15th. TD Cowen cut Repare Therapeutics to a “hold” rating in a research note on Monday, November 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Repare Therapeutics in a research report on Monday, December 22nd. Finally, HC Wainwright decreased their price objective on shares of Repare Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a report on Monday, October 27th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Repare Therapeutics has an average rating of “Hold” and an average target price of $3.00.

Institutional Investors Weigh In On Repare Therapeutics

Large investors have recently modified their holdings of the business. Acadian Asset Management LLC lifted its position in shares of Repare Therapeutics by 35.6% during the first quarter. Acadian Asset Management LLC now owns 640,332 shares of the company’s stock worth $624,000 after purchasing an additional 168,230 shares in the last quarter. Quinn Opportunity Partners LLC acquired a new position in Repare Therapeutics in the second quarter valued at approximately $56,000. XTX Topco Ltd purchased a new stake in Repare Therapeutics in the second quarter valued at $60,000. Militia Capital Partners LP acquired a new position in Repare Therapeutics during the second quarter worth approximately $166,000. Finally, Rangeley Capital LLC acquired a new position in Repare Therapeutics in the 2nd quarter valued at about $494,000. Hedge funds and other institutional investors own 85.09% of the company’s stock.

Repare Therapeutics Company Profile

Repare Therapeutics, traded on NASDAQ under the symbol RPTX, is a clinical-stage biopharmaceutical company focused on the discovery and development of precision oncology medicines. The company applies synthetic lethality—a concept whereby cancer-specific genetic vulnerabilities are exploited—to design small-molecule therapies that selectively kill tumor cells while sparing healthy tissue. Repare’s proprietary functional genomics and screening platform integrates CRISPR-based assays and computational biology to systematically uncover novel genetic interactions and therapeutic targets.

At the core of Repare’s approach is its ability to identify and validate DNA damage response (DDR)-related targets.